Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk myelodysplastic syndrome.

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

A NEW study has explored the effects of combining nivolumab, an immunotherapy drug, with hypofractionated radiotherapy in ...